MK-0952

• UNSPSC Description:

  MK-0952 is a selective and orally active PDE4 inhibitor, with an IC50 of 0.53 nM. MK-0952 has the potential for Alzheimer’s disease study[1][2].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/mk-0952.html

• Purity:

  99.71

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1[C@H](C2=CC=C(C3=CC=CC(N4C=C(C(NC5CC5)=O)C(C6=C4N=CC=C6)=O)=C3)C=C2F)C1)O

• Molecular Weight:

  483.49

• References & Citations:

  [1]Michel Gallant, et al. Discovery of MK-0952, a Selective PDE4 Inhibitor for the Treatment of Long-Term Memory Loss and Mild Cognitive Impairment. Epub 2010 Sep 21.|[2]Tingting Pan, et al. Dual Functional Cholinesterase and PDE4D Inhibitors for the Treatment of Alzheimer's Disease: Design, Synthesis and Evaluation of tacrine-pyrazolo[3,4-b]pyridine Hybrids. Behav Brain Res. 2016 Apr 15;303:26-33.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Phase 2

• CAS Number:

  934995-87-6